We have discovered that an under-estimated and largely forgotten structure on the blood vessel wall, the glycocalyx, is cleaved off by immune cells in specific patterns before they invade the organ to cause harm. 

These patterns can be extracted and assembled from a blood sample, like a fingerprint for active disease.

We call this the GLX Signature


In Multiple Sclerosis, a devastating disease attacking the brain, an individual experiences symptoms and receives an MRI.  They don’t know if they’ll have relapsing attacks, progress to a wheelchair, or even have no symptoms for the rest of their life. An MRI can only follow brain damage after damage has occurred, and is extremely expensive.


The discovery of the GLX Signature can help. In practice it’s a composite biomarker of inter-related components of the GLX. From these patterns, we build the GLX Signature.

Since our GLX Signature reflects early disease activity, before damage has occurred in the brain, it can be implemented as a monitoring system, both for patient attacks and treatment effect. In some respects, like a blood MRI.

By monitoring this signature, diagnosis improves, and most exciting: attacks can be predicted and treatments monitored in better detail, improving health, and keeping people out of the hospital.

Right treatment, right person, right time

Personalised medicine means not just shifting through the medicine of the day, but also facilitating the discovery, development and market approval of new and better interventions, with less side-effects.